$SRRK

Scholar Rock Holding (SRRK) received FDA approval for ISEMBYLD, a treatment for spinal muscular atrophy in patients aged 2+. The drug showed a 2.2-point advantage over placebo in motor ability tests. The company is launching the product in the U.S., with support programs for insurance and infusions. Commercial success depends on patient access and treatment persistence, with safety concerns and reimbursement terms being key factors.

Scholar Rock received FDA approval for Isembyld, a drug targeting muscle loss in spinal muscular atrophy (SMA). The approval follows successful clinical trials showing improved motor skills in patients. The drug is approved for use with existing SMA therapies. Scholar Rock, valued at $6.8B, addressed manufacturing issues before resubmission. Pricing details are pending.

Analysts downgraded several stocks: HSBC cut Banco Santander Brasil (BSBR) to Hold with a $6.2 target; Rosenblatt downgraded Ribbon Communications (RBBN) to Neutral with a $2.2 target; Citizens downgraded Cellectis (CLLS) to Market Perform; Barclays downgraded Scholar Rock (SRRK) to Equal-Weight with a $58 target; Raymond James downgraded Ascendis Pharma (ASND) to Outperform with a $287 target.

Wall Street analysts issued research calls on several companies. Eli Lilly (LLY) was upgraded to Buy with a $1,400 target, Etsy (ETSY) to Outperform with a $525 target, and New York Times (NYT) to Buy with an $82 target. Downgrades included Aptiv (APTV) to Neutral with a $56 target, Lear (LEA) to Neutral with a $150 target, and Magna (MGA) to Neutral with a $72 target. New initiations included Autodesk (ADSK) with a Neutral rating and $215 target, Rivian (RIVN) with a Neutral rating and $18 targ

Barclays downgraded Scholar Rock (SRRK) to Equal Weight, raising its price target to $58. The move follows FDA approval of Isembyld, but Barclays cites valuation concerns. SRRK's P/S ratio is 30.4x, and its GF Score is 29/100, indicating financial challenges. Insider activity shows balanced buying and selling.

Raymond James increased its price target on Scholar Rock (SRRK) to $72 from $65, maintaining a Strong Buy rating. The FDA approval of ISEMBYLD for SMA could lead to a quick U.S. launch, with potential $2.2B revenue by 2035, according to the analyst.

Elmet Group (ELMT) surged 35.55% after a $450M DoD investment. Baldwin Insurance (BWIN) rose 7.66% on a $7.7B take-private deal. Scholar Rock (SRRK) fell 4.07% despite FDA approval. RUM Group (RUM) gained 15.41% on a $13.7B GPU deal with Anthropic.

US futures decline as tech stocks, particularly AI-linked ones, fall due to concerns over slower AI development. Nvidia, Tesla, and Meta are among the decliners, while oil prices rise. Brent crude approaches $108/barrel. Bond yields show mixed movements. Several companies, including Corning and Scholar Rock, see significant premarket moves. Fed and BoJ rate decisions are upcoming.

Scholar Rock (SRRK) shares rose 9.1% to $60.45 after FDA approved ISEMBYLD for spinal muscular atrophy. The treatment targets adults and children aged 2+ on SMN2-targeted therapy. Analysts raised price targets, with Truist, Raymond James, and Citi citing strong potential. SRRK has $492M in cash and prepares for commercial launch.

Scholar Rock Holding Corp (SRRK) stock rose 9.1% to $60.45 after the FDA approved its drug ISEMBYLD for spinal muscular atrophy. Analysts raised price targets, with Truist Securities at $76, Raymond James at $72, and Citi at $74, citing strong revenue potential. The company has $492 million in cash and is ready to commercialize the drug.